Teleflex Incorporated Intrinsic Stock Value – TELEFLEX INCORPORATED Reports 5.5% YOY Increase in Total Revenue for FY2023 Q2

☀️Earnings Overview

On August 3 2023, TELEFLEX INCORPORATED ($NYSE:TFX) announced its Q2 FY2023 earnings results with total revenue amounting to USD 743.3 million, a 5.5% increase from the same period in the prior year. This was accompanied by a 5.5% year-on-year rise in net income, bringing the total to USD 111.3 million.

Analysis – Teleflex Incorporated Intrinsic Stock Value

GoodWhale has conducted an in-depth financial analysis of TELEFLEX INCORPORATED. Our proprietary Valuation Line has determined that the fair value of a TELEFLEX INCORPORATED share is around $300.0. Currently, TELEFLEX INCORPORATED shares are trading at $239.5, representing a 20.2% discount to the fair value. This could be an attractive opportunity for investors looking to buy undervalued stocks. Furthermore, our analysis suggests that the stock is likely to appreciate in the future as it reaches its fair value. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Teleflex Incorporated. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Teleflex Incorporated. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Teleflex Incorporated. More…

Key Ratios Snapshot

Some of the financial key ratios for Teleflex Incorporated are shown below. More…

Peers

Teleflex Inc., a leading global provider of medical technologies, offers a broad range of products and services for use in critical care and surgery. The company’s products are used by hospitals and other healthcare facilities worldwide. Teleflex’s competitors include Delta Asia International Corp, Meihua International Medical Technologies Co Ltd, and Shanghai Sanyou Medical Co Ltd.

– Delta Asia International Corp ($TPEX:6762)

Daiwa-Asia International Corp is a leading provider of financial services in Asia. The company offers a wide range of products and services, including banking, insurance, asset management, and securities brokerage. Daiwa-Asia has a strong presence in the region, with operations in Hong Kong, Singapore, Taiwan, China, and Japan. The company is listed on the Tokyo Stock Exchange and has a market capitalization of 5.54 billion as of 2022. Daiwa-Asia reported a return on equity of 11.54% for the year ended March 31, 2022.

– Meihua International Medical Technologies Co Ltd ($NASDAQ:MHUA)

Meihua International Medical Technologies Co Ltd is a Chinese medical technology company. It has a market cap of 191.52M as of 2022 and a Return on Equity of 16.31%. The company develops, manufactures, and sells medical devices and equipment. Its products include stents, catheters, and other cardiovascular products.

– Shanghai Sanyou Medical Co Ltd ($SHSE:688085)

Shanghai Sanyou Medical Co Ltd is a medical company with a market cap of 7.06B as of 2022 and a Return on Equity of 8.19%. The company specializes in the manufacture and sale of medical equipment and supplies. It is headquartered in Shanghai, China.

Summary

Teleflex Incorporated reported strong financial results for its second quarter of the fiscal year 2023, showing a 5.5% year-on-year increase in total revenue, amounting to USD 743.3 million, and a net income of USD 111.3 million, also up 5.5%. Despite these strong results, investors reacted negatively to the announcement, as the stock price moved down on the same day. Investors should pay close attention to future earnings releases from Teleflex Incorporated to get an accurate picture of the company’s performance. Moreover, it is important to consider the company’s strategies for growth and how it plans to continue increasing revenue and profits in the long-term.